CBD Shows Multi-Target Potential Against Breast Cancer Pathways, Study Finds
- CBD strongly binds to four key proteins involved in breast cancer progression—CDK6, BCL2, MMP2, and VEGFR2—highlighting its potential as a multi-target treatment option.
- CBD’s binding affinities were comparable to existing cancer drugs like palbociclib, ABT-199, doxycycline, and axitinib, suggesting effective interaction with breast cancer-related protein targets.
- The study emphasizes CBD’s promise in addressing multiple biological pathways in breast cancer, including cell proliferation, apoptosis resistance, metastasis, and angiogenesis, potentially offering a broader therapeutic approach.
- While CBD’s favorable safety profile supports its therapeutic potential, the findings are based solely on computational models, and further laboratory and clinical studies are necessary to confirm its anti-cancer effects.
The cannabis compound cannabidiol (CBD) interacts strongly with several proteins tied to breast cancer growth and spread, highlighting its potential as a multi-target treatment candidate, according to a new study published in Current Drug Discovery Technologies. Researchers from Amity University and Assam Down Town University in India used molecular docking to examine how CBD binds with four proteins that play major roles in breast cancer progression. These included CDK6, which helps regulate the cell cycle; BCL2, a protein linked to resistance to apoptosis; MMP2, which is associated with invasion and metastasis; and VEGFR2, a receptor involved in angiogenesis, the process through which tumors form new blood vessels.
According to the study, CBD showed strong binding affinities across all four targets. The researchers compared CBD’s performance to standard inhibitors already used as reference compounds for each pathway, including palbociclib, ABT-199, doxycycline and axitinib. They found that CBD’s docking scores were comparable to those drugs, suggesting it may interact effectively with the active sites of proteins involved in breast cancer development.
The findings are notable because breast cancer progression is driven by multiple overlapping biological processes, including unchecked cell proliferation, the ability of cancer cells to avoid programmed cell death, the spread of tumors to other parts of the body, and the growth of blood vessels that feed tumors. A compound capable of targeting several of those pathways at once could offer a broader therapeutic strategy.
Researchers say CBD’s favorable safety profile adds to its appeal as a possible treatment candidate. However, they also caution that the results are based on computational modeling, not laboratory or clinical testing. They say further in vitro and in vivo research will be needed to determine whether these interactions translate into measurable anti-cancer effects in living systems.
This latest paper adds to a growing run of recent research tying marijuana compounds to potential breast cancer applications. For example, in just the past two months, studies have found that CBD selectively impaired HER2-positive breast cancer cells and triggered distinct cell-death pathways, that an exosome-based oral CBD formulation slowed aggressive triple-negative breast cancer in mice while altering more than 1,000 cancer-related genes, and that a CBC-CBD combination shrank drug-resistant triple-negative breast cancer tumors in lab and animal models, among others.